Physician profile
Mark D Clark
NPI 1285631887
$10,380.30
in general payments reported to CMS, 2019-2025
55 companies · $2,919 in 2025
The $2,919 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,296 · 2022: $1,089 · 2023: $2,317 · 2024: $1,759 · 2025: $2,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,850 · Consulting Fee: $932 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,849.85 |
| Consulting Fee | $932.00 |
| Education | $213.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,070.33 | 2024-2025 | Libtayo |
| Exelixis INC. | $867.39 | 2021-2025 | Cabometyx |
| Janssen Biotech, INC. | $609.28 | 2021-2025 | Darzalex, Talvey, Imbruvica |
| Seagen INC. | $484.86 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Abbvie INC. | $474.86 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $461.23 | 2021-2025 | Tagrisso, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $430.43 | 2021-2025 | Opdivo, Opdualag |
| Celgene Corporation | $379.28 | 2021-2025 | Reblozyl |
| Pfizer INC. | $364.90 | 2021-2025 | |
| Eisai INC. | $355.51 | 2021-2025 | |
| Incyte Corporation | $327.76 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Jazz Pharmaceuticals INC. | $304.87 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.86 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $301.13 | 2021-2023 | Imbruvica |
| Amgen INC. | $290.90 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $275.79 | 2021-2025 | |
| Daiichi Sankyo INC. | $258.93 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $189.84 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Deciphera Pharmaceuticals INC. | $188.31 | 2021-2025 | Qinlock, Tgct, Romvimza |
| Merck Sharp & Dohme LLC | $170.88 | 2021-2025 | Keytruda, Welireg |
| Gilead Sciences, INC. | $153.62 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $146.55 | 2021-2025 | Padcev, Xtandi |
| Glaxosmithkline, LLC. | $138.51 | 2021-2024 | Ojjaara, Shingrix |
| Eagle Pharmaceuticals, INC. | $137.60 | 2023 | |
| Beigene USA, INC. | $131.41 | 2021-2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $110.07 | 2024 | Myrisk |
| Kite Pharma, INC. | $103.25 | 2021-2025 | Yescarta |
| Karyopharm Therapeutics INC. | $94.41 | 2021-2025 | Xpovio |
| Epizyme, INC. | $85.43 | 2021-2023 | Tazverik |
| Ipsen Biopharmaceuticals, INC | $82.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.69 | 2021-2024 | |
| G1 Therapeutics, INC. | $76.82 | 2023 | Cosela |
| Adaptive Biotechnologies Corporation | $72.50 | 2023-2025 | Clonoseq |
| Morphosys, US INC. | $69.44 | 2021-2023 | Monjuvi |
| Puma Biotechnology, INC. | $69.25 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $64.83 | 2023-2024 | Libtayo |
| Array Biopharma INC | $63.78 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Adc Therapeutics America, INC. | $60.22 | 2021-2024 | |
| Genentech USA, INC. | $55.20 | 2022-2025 | Polivy, Venclexta |
| Sobi, INC | $55.18 | 2024-2025 | |
| Tersera Therapeutics LLC | $48.92 | 2021-2025 | Zoladex |
| Beone Medicines USA, INC. | $47.88 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $47.48 | 2022-2024 | Pyrukynd |
| Emd Serono, INC. | $44.56 | 2021 | |
| Stemline Therapeutics INC. | $33.85 | 2025 | Orserdu |
| Coherus Oncology, INC. | $27.75 | 2021 | |
| Sumitomo Pharma America, INC. | $22.10 | 2023 | Orgovyx |
| Pharmaessentia USA Corporation | $21.76 | 2025 | Besremi |
| Lilly USA, LLC | $20.28 | 2024 | Retevmo, Jaypirca, Verzenio |
| Legend Biotech USA INC. | $19.82 | 2025 | Carvykti |
| Corcept Therapeutics | $18.50 | 2025 | Korlym |
| Progenics Pharmaceuticals, INC. | $18.01 | 2025 | |
| Aveo Pharmaceuticals, INC. | $17.30 | 2022 | |
| Servier Pharmaceuticals LLC | $15.75 | 2023 | |
| Taiho Oncology, INC. | $14.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.